Tesofensine vs Tirzepatide
How Tesofensine and Tirzepatide compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
Tesofensine and Tirzepatide come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
Tesofensine vs Tirzepatide, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | Tesofensine | Tirzepatide |
|---|---|---|
| What it is | Synthetic small-molecule triple monoamine-reuptake inhibitor (a tropane derivative — not a peptide) | Synthetic dual GIP/GLP-1 receptor agonist (a 39-amino-acid once-weekly injectable peptide) |
| Class / category | Incretin / metabolic | Incretin / metabolic |
| Evidence tier | Human RCT · Helped | Human RCT · Helped |
| Studied / approved for | Weight loss / obesity; Parkinson's disease; Alzheimer's disease; Hypothalamic obesity; Prader-Willi syndrome | Type 2 diabetes (Mounjaro); Chronic weight management in obesity/overweight (Zepbound); Moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound) |
| US regulatory status (2026) | research use only (as of Jul 2026) | fda approved (as of Jul 2026) — approved for Type 2 diabetes (Mounjaro), Chronic weight management in obesity/overweight (Zepbound), Moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound) |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | 13 | 261 |
| Banned in sport (WADA) | Yes — on the WADA prohibited list | No |
| Key risks | Tesofensine's main safety problem is cardiovascular: because it raises noradrenaline and dopamine, it tends to push up heart rate and blood pressure, and that — not a lack of effect — is why its obesity development stalled. Human trials also reported dry mouth, insomnia, nausea, constipation and mood or agitation changes. There is no long-term human safety record, and the research-market product is unregulated. | Tirzepatide's most common side effects are gastrointestinal: nausea, diarrhea, vomiting and constipation, heaviest while the dose is being raised and usually settling as the body adjusts. Less common but serious are acute pancreatitis, gallbladder disease, dehydration that can injure the kidneys, and low blood sugar when it is paired with insulin or a sulfonylurea. It carries a boxed warning for thyroid C-cell tumors seen in rats (human relevance unknown) and must not be used by anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. The approved pen is the product the trials measured; self-mixed "research" powder is a separate, untested risk. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
Tesofensine vs Tirzepatide: the two molecules
The 2D chemical structures, straight from PubChem — a quick way to see how similar (or not) the two actually are.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
If you want an FDA-approved, prescribable option
Leans toward Tirzepatide
Tirzepatide is FDA-approved (as of Jul 2026); Tesofensine is research use only in the US, so it isn't available as an approved prescription.
References
- 1.Tesofensine — indexed research (PubMed, National Library of Medicine)
- 2.Tesofensine — registered clinical studies (ClinicalTrials.gov)
- 3.Tesofensine weight-reduction Phase 2 trial (ClinicalTrials.gov NCT00394667)
- 4.Drugs@FDA — approved drug database (no tesofensine product listed)
- 5.Drugs@FDA — tirzepatide (Mounjaro, Zepbound) approval records
- 6.Tirzepatide prescribing information (DailyMed)